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A STUDY OF THE DEPRESSOR AFTEREFFECTS OF NOREPINEPHRINE
CHAPTER I
INTRODUCTION
Norepinephrine has been u t i l iz e d  as a pressor agent to combat
hypotensive s ta te s  in  p a tie n ts  s in ce  1949. The f i r s t  report of th is
u se , published by Goldenberg e t  a l .  ( 1 ) ,  in d ica ted  th at norepinephrine
was b e n e f ic ia l  in  co rrectin g  acute hypotension in  22 of 23 p atien ts
during and fo llow in g  thoracolumbar sympathectomy. S ince th at tim e,
norepinephrine has been found u se fu l in  reversin g  the sh o ck -lik e  s ta te s
^hich freq u en tly  occur in  con d ition s such as p e r i t o n i t i s ,  myocardial
in fa r c t io n , removal of pheochromocytoma, hemorrhage, epidemic hemorrhagic
fev e r , trauma, surgery of a l l  kinds and sp in a l a n e s th e s ia .1 2 ,3 ,4 ,5 ,6 ,7 ) .
Some in te r e s t in g  phenomena have been noted as a r e su lt  of the 
' ! 
increased  therap eu tic  use of norepinephrine to co rrect sh ock -lik e  !
s t a t e s .  I t  has been found th a t some p a tie n ts  who r e ce iv e  norepinephrine!
!
over periods of se v e r a l hours to  severa l days require increasing  doses !
:  I
of the agent in  order to  m aintain the blood pressure at a norraotensive ! 
'lev e l. Furthermore, a fte r  long-continued in fu sio n  of norepinephrine, a 
number of p a tie n ts  have been noted who do not to le r a te  abrupt removal of
! I
[the drug without return ing to  an hypotensive s ta te .  In th is  even t, the
I
dose of norepinephrin e must be slow ly decreased over a period of Jtime__
1
2u n t i l  i t  can be s a fe ly  stopped. This pKe home non has a lso  been repeated ly
[
observed during surgery for removal of the norepinephrine-epinephrine- 
producing tumor, pheochromocytoma. During l ig a t io n  and e x c is io n  of these  
tumors, the p a tien ts  develop an acute and profound hypotension in  
v ir tu a lly  every in sta n ce . An immediate in fu sio n  of norepinephrine w i l l  
return the blood pressure to  normal in  most ca ses . Here again , a weaning 
process must be used to d iscontinue in fu sio n  of the drug.
In the present study the vasodepressor a f te r e f f e c t  of nor­
epinephrine was produced by in fu sin g  dogs w ith high doses of norepi­
nephrine over a period of severa l hours, A long-term in fu sio n  in  dogs 
in variab ly  shows two d is t in c t  e f f e c t s ;  1) during in fu sio n  the blood 
pressure r is e s  p r e c ip ito u sly  a t f i r s t ,  but in  a few minutes gradually  
d e c lin e s  u n t i l  i t  even tu ally  a tta in s  or f a l l s  below p re-in fu sio n  le v e ls ;  
2) a fte r  d iscon tin u in g  the in fu sio n , the blood pressure f a l l s  to  an even 
lower le v e l .
The purpose of th is  in v e st ig a tio n  has been to  study the 
mechanism or mechanisms resp onsib le  for the depressor e f f e c t  of n orep i-  
Inephrine both during and fo llow in g  long-term  in fu sion . In the v a st
I
I litera tu re  concerning the p h y s io lo g ica l and pharmacological a c tio n s  of 
both norepinephrine and epinephrine, c e r ta in  properties have been 
{described which might account for th is  phenomenon.
This study has attempted to t e s t  the p la u s ib i l i t y  of the  
fo llow in g  p o ss ib le  mechanisms as a cause for  the vasodepressor a f te r -  
le f fe c ts  of norepinephrine:
1. Autonomic ganglion ic b locking a c tio n  of norepinephrine, 
-------------- liicreased -in activa tion -o f-n orep in ep h rin e;---------------------------------
33. Decreased response of the cardiovascular system to nor­
epinephrine.
4. E laboration in to  the c ir c u la t io n  of vasodepressor m aterial 
(VDM) as a response to  norepinephrine.
5. Hypoglycemic hypotension as a response to  norepinephrine.
CHAPTER II
HISTORY
I Norepinephrine Was f i r s t  syn thesized  by S to ltz  ( 8 ) ,  in  1904.
I
He a lso  made the f i r s t  observations concerning some of i t s  b io lo g ic a l  
p ro p er tie s , noting for  example, th a t i t  was as potent as epinephrine 
w ith resp ect to  i t s  pressor e f f e c t  but le s s  to x ic  (9 ) .  The period from 
1904 to 1946 y ielded  l i t t l e  inform ation regarding the pharm acological an 
p h y s io lo g ic a l ro le  of norepinephrine. This lack of inform ation was a 
j lirec t consequence of the fa c t  that most in v e st ig a to r s  regarded e p i-  
pephrine to  be the so le  adrenal medullary hormone. However, there were 
some in tim ation s that epinephrine was not the s o le  adrenergic nerve 
jtransmittor as early  as 1910 when Barger and Dale (10) published th e ir  
c la s s ic a l  paper, "Chemical stru ctu re  and sympathomimetic a c tio n  of |
amines". They r e a lize d  that the a c tio n s  of epinephrine deviated  in  
some resp ects from those obtained by stim u la tion  of sympathetic nerves, j
;  i
The s ig n if ic a n c e  of th is  work was not gen era lly  recognized or further j
pursued u n t i l  Cannon and Rosenbleuth, in  1933, revealed  the appearance i
; !
of a factor  other than epinephrine fo llow in g  sympathetic nerve stirau- '
:  I
la t io n  (1 1 ). In 1934, Bacq (12) suggested  th at the sympathin E and I of; 
Cannon and Rosenbleuth were id e n t ic a l ,  r e sp e c t iv e ly , w ith norepinephrine 
and jzp iaephrine. . Although the terms sympathin.E .and. sympathin I  are no_
5longer used because th e ir  connotations aré somewhat erroneous, th is  worki 
provided the impetus for the in v e s t ig a tio n s  of Euler who from 1946 to  |
I
1948 published  papers showing th at ex tra c ts  of adrenergic nerves, and the 
organs supp lied  by them, contained appreciable q u a n titie s  of norepi­
nephrine. From the reports of Euler and o th ers , i t  i s  now gen era lly  |
; I
accepted th at norepinephrine i s  the adrenergic nerve m ediator, although |
I
. Ii t  i s  recognized that epinephrine i s  a lso  present a t adrenergic nerve | 
^ndings. The consensus, at p resen t, i s  th a t norepinephrine i s  the 
chemical mediator a t p ostgan g lion ic  adrenergic nerve endings and ep i­
nephrine i s  the c ir c u la t in g  hormone elaborated  by the adrenal medulla (1 3 ).
Formation of Norepinephrine and Epinephrine 
The mechanism of the b io sy n th es is  of norepinephrine and ep i­
nephrine i s  s t i l l  la r g e ly  unknown. The most important con tr ib u tio n s, to  
what seems to  be the most probable mode of form ation of norepinephrine, 
have come from H oltz , H eise and Ludtke (14) who discovered Dopa-decar- 
boxylase; and Blaschko (15) who proposed a r e a ctio n  s e r ie s  includ ing  
norepinephrine. The b io sy n th es is  may t e n ta t iv e ly  be assumed to  take the 
fo llow in g  course: 1) 3 ,4-dihydroxyphenylalanine (Dopa) derived from ;
i  i
tyrosin e  or phenyla lan in e, lo se s  CO2  by the a c tio n  of Dopa-decarboxylase, 
to  form hydroxytyramine; 2) hydroxytyramine i s  ox id ized  to form nor- :
I  i
epinephrine; 3) norepinephrine i s  m ethylated to  form epinephrine. This I
: i
reaction  i s  supported by a f a ir  amount of ev id en ce, although circum­
s ta n t ia l  in  some regards. Two other precursors of norepinephrine have i
been suggested ; dihydroxyphenylserine by B laschko, Burn and Langemann ( l l ) ,
j
In 1950, and Schmiterlow (1 7 ) , in  1951, and p-hydroxyphenylethanolamine
6(octopamine) by Erspamer (1 8 ) , in  1952.
The qu estion  of whether norepinephrine i s  a lso  a precursor of j 
epinephrine, in  ad d ition  to i t s  independent b io lo g ic a l a c tio n , has been 
answered in  the a ffirm a tiv e  by Bulbring ( 1 9 ) ,  in  1949; and la te r  by 
Masuoka, S ch o tt, Akawie and Clark (2 0 ) , in  1956. Masuoka e t  a l . ,  in ­
je c te d  a-C ^^-arterenol in tr a p e r ito n e a lly  in to  ra ts  and found C^^-epi- 
nephrine in  the adrenal g lands. The use of rad ioactive  carbon la b e lled  
compounds by Udenfriend and Wyngaarden ( 2 1 ) ,  in  1956, has a lso  provided 
us w ith  good evidence that 3,4-dihydroxyphenylalanine, and 3,4-dihydroxy- 
phenethylamine are precursors of epinephrine and norepinephrine in  v ivo . 
P e lle r in  and D *Iorio , in  1957, stud ied  the metabolism of d l-3 ,4-d ihydroxy  
phenylalanine a-C l4 in  bovine adrenal horaogenate and found good y ie ld s  
of C ^^-labelled  norepinephrine but no epinephrine (2 2 ). They were a lso  
ünable to d e te c t  any 3 ,4-dihydtoxyphenyIserine which led  them to  postu­
la te  that th is  compound was not in  the m etabolic pathway from tyrosine  
to  norepinephrine.
In a c tiv a tio n  and E lim ination  of Norepinephrine and Epinephrine
The p o ss ib le  routes of in a c t iv a t io n  and e lim in ation  of nor- |
i
!
epinephrine appear to  be the fo llow in g : j
1, O xidative deamination by amine oxidase. j
' 2. O xidation by cytochrome oxidase system s, ca tech o l ox id ase ,!
: I
dopa-oxidase, adrenalinedehydrogenase, peroxidase-peroxide system s.
: i
3. Conjugation (e th e r e a l su lp h a tes , g lucuron id es). ;
i
4. E xcretion  in  the free  form. I
O xidative Deamination by Amine Oxidase
! The e f f e c t  of amine oxidase i s  to  cause an ox idative dearai-
1
nation of monoamino compounds such as norepinephrine. Norepinephrine i s  
thus oxidized to an aldehyde with the lib e r a t io n  of NH .^ The aldehyde 
may then be further oxid ized  to  dihydroxyphenylglycolic acid  by aldehyde
oxidase.
!
! The ro le  of the amine oxidase system as a means of in a c tiv a tio n
j
pf norepinephrine in  v ivo  has been a su b ject of much controversy. Many 
|of the e a r lie r  in v e s t ig a to r s , such as R ichter and Tingey (2 3 ) , have d is ­
counted the e f f ic a c y  of th is  enzyme because of the slow deamination of
I
norepinephrine in  v i tr o ,  w hile recent observations have tended to  s tr e s s  
t h is  way of in a c tiv a tio n .
A recent s e r ie s  of papers by Burn and h is  co-workers has been 
devoted to the problem of the p h y s io lo g ica l importance of amine oxidase. 
These in v e st ig a tio n s  were prompted by the s tu d ies  of Blaschko, R ichter, 
and Schlossmann (2 4 ) , in  1937, and Gaddum and Kwiatkowski (2 5 ) , in  1938,
on the e f f e c t s  of ephedrine. Gaddum and Kwiatkowski concluded that the !
i
b io lo g ic a l  a c t iv i ty  of ephedrine was due to  i t s  in h ib it io n  of amine 
oxidase, thus, p o te n tia tin g  the action  of epinephrine.
Schapira, in  1945, demonstrated that amine oxidase was present 
in  every t is s u e  te s te d  (2 6 ). Bain and D ickinson, in  1950, showed that  
l iv e r  contained amine oxidase and was capable, in  v itr o ,  of the in a c t i -  j
vation  of epinephrine in  various s p e c ie s , includ ing man (2 7 ) . The j
presence of amine oxidase in  the i r i s  and n ic t i ta t in g  membrane of the
8cat and rabb it was reported by Robinson ( 28) ,  in  1952.
Blaschko and Burn, in  1951, reported that amine oxidase has a 
greater preference for norepinephrine than i t  does for  epinephrine (2 9 ). 
This fa c t  added support to  the work of Burn and Robinson, in  1951, who 
observed that ephedrine added to  the f lu id  perfusing a ra b b its’ ear in ­
creased the v a socon str ictor  a c tio n  of norepinephrine more than i t  d id  
that of epinephrine (3 0 ). In accordance w ith  th is  theory , ephedrine 
io e s  not a lte r  the a c t iv i ty  of cobefrine (c o r b a s il)  which i s  not a sub­
s tr a te  for  amine oxidase.
Burn and Robinson, in  1952, stu d ied  the amine oxidase content
of the in ta c t ,  and denervated n ic t i ta t in g  membrane (3 1 ) . I t  was found
i
that 10 to  12 days fo llow ing denervation , the amine oxidase a c t iv i ty  
f e l l  to  66 per cen t of normal. They a ls o  found th at the membrane was 
more s e n s it iv e  to  norepinephrine when there was a reduction  of the 
enzyme a c t iv i t y .  The amount o f enzyme a c t iv i ty  in  the denervated mem­
brane gradually returned toward normal a fte r  about 10 days; and a fte r
i
33 days, the enzyme a c t iv i ty  a tta in ed  a normal le v e l .  From these exp er i-
!
raents, i t  i s  in ferred  that amine oxidase at the adrenergic nerve endings j 
has a fu n ction  s im ila r  to th at of ch o lin e ster a se  at ch o lin erg ic  nerve
endings. ;
!
: !
The observations of Innes and K o ste r litz  (3 2 ) , in  1951, on thei
' !
e f f e c t  of coca in e , and of denervation , on the p o s it iv e  chronotropic |
e f f e c t  of norepinephrine on the heart might be a t le a s t  p a r tly  explained}
: I
along these l in e s .  I
I
I II j
C atechol and Cytochrome Oxidase. Peroxidases |
9C atechol ox idase, which i s  a copper p ro te id e , has been reported
to  in a c tiv a te  epinephrine. Cytochrome ox id ase, dopa-oxidase, and p erox i-
!
Üase-peroxide system s have a lso  been found capable of in a c tiv a tin g  e p i-  j  
nephrine but most o f the work was done in  v itr o  w ith l i t t l e  evidence
that the processes occur in  v ivo .
i Conjugation (E thereal S u lfa te s ,  G lucuronides)
I
R ich ter , in  1940, found th at a f te r  the adm inistration of
r e la t iv e ly  large q u a n titie s  of c e r ta in  ca tech o l amines to  human su b jects
a su b sta n tia l amount appeared in  the urine in  a coryugated form (3 3 ).
On the b a s is  of th is  work many considered conjugation to  be a major
pathway for  the e lim in a tio n  of these amines.
Schayer (3 4 ) ,  in  1951, stu d ied  the urinary excretion  pattern  
of d l-ad ren alin e  la b e lle d  in  two ways w ith  C^^. One compound was C^^-
la b e lled  in  the N-methyl group, and a second was la b e lle d  in  the B
carbon p o s it io n . A fter intravenous in je c t io n s  of B-C^^-adrenaline in  
r a ts , there were no conjugates d etected  in  the urine in d ica tin g  that 
Conjugation i s  not a route of in a c t iv a t io n  under p h y s io lo g ic a l con d ition s  
When large  q u a n tit ie s  of B-C^^-adrenaline were fed to r a ts , considerable  
q u a n titie s  of conjugated adrenaline were found in  the u rine. This con­
ju gation  presumably occurred in  the in te s t in e  or l iv e r .  Although a l l  
of the C^  ^ of sm all q u a n titie s  of B-^l^^-adrenaline was excreted in  the 
urine o f r a ts  in  4 hours, under s im ila r  con d ition s only s l ig h t ly  more 
than h a lf  of the adm inistered from the N -m ethyl-labelled  compound 
was excreted . Schayer concluded from t h is  work that a reaction  involv ing  
cleavage of the m olecule between the B and N-methyl carbon atoms
10
c o n s titu te s  a major pathway of metabolism.
These fin d in gs by Schayer add to  the theory that destruction  
by amine oxidase i s  a major factor  in  the in a c tiv a tio n  of norepinephrine 
and epinephrine because a s p l i t t in g  of the compounds between the B and 
N-methyl carbon atoms could be accounted for by the action  of th is
enzyme.
!
I
E xcretion in  the Free Form 
Euler (35 ) s ta te s  th at in  h is  experience only a very sm all 
mount of norepinephrine and epinephrine are excreted in  the free  form. 
By in fu sio n  experiments he could find  only 1 .5  to  4 per cent of the 
adm inistered norepinephrine and 0 .5  to  1 per cent of the epinephrine in  
urine in  the free  form. Acid hydrolysis of the urine increased the 
quantity  recovered to  a to ta l  of about 6 per cen t which ind icated  that 
a portion, was conjugated. In the presence of a pheochromocytoma where 
the excretion  of norepinephrine and epinephrine i s  g rea tly  increased ,
acid h yd ro lysis does not m ater ia lly  increase the quantity  of catechol
I
amines found.
I
Fluorescent Products of Norepinephrine and Epinephrine 
S o lu tion s of norepinephrine and epinephrine w il l  Undergo 
spontaneous oxidation  in  the presence of oxygen. This i s  p a r ticu la r ly  
true i f  the so lu tio n  i s  a lk a lin e . The products of norepinephrine and 
epinephrine ox id a tion , under these co n d itio n s , are flu o rescen t. The 
mechanisms of th is  rea ctio n  and the chemical nature of these compounds 
have been the ob ject of considerable study and have been ex ten siv e ly  
reviewed by E uler (-35).— Some very u se fu l in f  ormation has-evolved from—
11
these in v e s t ig a t io n s . The fa c t  that the oxidation  by-products of e p i­
nephrine and norepinephrine are flu orescen t has afforded a method for  
th e ir  q u an tita tive  and q u a lita t iv e  determ ination in  u r in e , blood and
j
t is s u e  (3 6 ,3 7 ,3 8 ,3 9 ,4 0 ,4 1 ). !
i
In an a lk a lin e  medium, epinephrine i s  ox id ized  p rogressive ly
fo  adrenochrome, adrenolutin , and f in a l ly  melanin. The oxidation  of
> I
norepinephrine proceeds in  the same fash ion  as that of epinephrine, ;
y ie ld in g  noradrenochrorae and noradrenolutin. Noradrenolutin has been i
characterized  as being 3;5;6-tr ih yd roxyin d ole. The compound i s  |
apparently in  equilibrium  between the enol and ketone form, I
I
Adrenolutin and noradrenolutin have been shown to condense j 
w ith ethylenediam ine to form condensation products which are as flu orescen t  
but much more sta b le  than the parent compounds. These condensation com-| 
pounds have been used by Weil-Malherbe and Bone for the q u a n tita tiv e  ! 
estim ation  of catechol amines in  both blood and urine (4 2 ,4 3 ,4 4 ,4 5 ,4 6 ),
The q u an tita tive  estim ation  of norepinephrine, epinephrine andi 
other ca tech o l amines by the photofluorim etric methods of Euler (4 7 ,4 8 , i 
4 9 ,5 0 ) , Weil-Malherbe and Bone, Goldenberg (5 1 ), Lund, and o th ers , i s  
probably the most accurate now a v a ila b le . However, these methods are 
s t i l l  only accurate to about 10 per c e n t, and are tec h n ic a lly  d i f f i c u l t  : 
to  perform. The accuracy i s  dependent upon the type of f lu o r imeter used; 
and the o p t ic a l f i l t e r s  a v a ila b le . V ariations in  apparatus have led  to  ; 
some d iffe r e n c e s , q u a n tita t iv e ly , between the r e su lts  obtained by in­
v e stig a to r s  who have used the same method. The same discrepancy of !
r e su lts  has been found repeatedly  by in v e stig a to r s  who use id e n tic a l  I
: ;
apparatus but s l ig h t  m od ification s of the same-method.
12
The Histamine -  Antihistam ine R elationsh ip  i
to  Epinephrine and Norepinephrine
i i
Staub reported, in  1946, th at an in je c t io n  of 0 .2  mg. of |
adrenaline, in  man, caused an in crease in  blood histam ine (5 2 ). I f  I  
0 .2  gra. of A n tistin e  (N-phenyl-N -benzylam inom ethylinidazoline) was given; 
3 to  9 minutes before adrenaline, the r is e  of blood histamine was pre­
vented. Baur and Staub compared the e f f e c t s  ot some sympathomimetic I
I
agents on blood histam ine le v e ls  in  man and ra b b it. They found that norl
I
epinephrine in creases blood histam ine le v e ls  in  the rabbit but not in  I 
man (5 3 ).
Euler (54) reported that histam ine was a s p e c if ic  co n stitu en t | 
of ce r ta in  autonomic nerve f ib e r s . The h igh est amount of histam ine was : 
found in  the postganglion ic  sympathetic f ib e r s  of the sp len ic , splanchnic  
and m esenteric nerves. The sp len ic  nerves of the ox were r ic h e s t  in  
norepinephrine and a lso  histam ine. This and other work by Rexed and 
Euler (5 5 ) , supports the idea of a d e f in it e  c o r re la tio n  between norepi­
nephrine and histam ine in  adrenergic nerves. This may, in  some way, be '
i
re la ted  to  the fa c t  that histam ine has the a b i l i t y  to  r e lea se  ca tech o l 
amines from chromaffin c e l l s .
Loew, MacMillan and K aiser stu d ied  the pharmacological a c t iv i ty  
of the an tih istam in e , Benadryl (B-dime thy1-aminoe thyIbenzhydryle  the r 
K l ) ,  and reported that i t  augmented the pressor e f f e c t  of epinephrine 
(5 6 ). At about the same time Yonkraann and h is  group, noted that the 
an tih istam in ic  agent, Pyribenzamine H21 ( N' -pyridy1-N ' benzy1-N-dimethy1- 
ethylened iam ine), a lso  augmented the pressor e f f e c t  of epinephrine (5 7 ).
13
LaBelle and Tislow reported the p o te n tia tin g  e f f e c t  of Trimeton (prophen- 
pyridamine) on the pressor e f f e c t  of epinephrine (5 8 ). Loew and Konrad 
showed th at some an tih istam in ics  in h ib ite d  epinephrine-induced hyper­
glycem ia in  rab b its  (5 9 ).
Tickner (6 0 ) , while searching fo r  an explanation of the a n ti­
histam ine-augm enting e f f e c t  on ep inephrine, showed that many of the 
a n tih ista m in ics  were amine oxidase in h ib ito r s . Piperoxan (933F) and 
dibenaraine, which are adrenergic b locking agen ts, were a lso  shown to be i 
s l ig h t ly  endowed with th is  property.
The l it e r a tu r e , un fortu n ately , does not contain adequate data  
on the r e la t iv e  an tih istam in ic  potency of the an tih istam in ic  agents 
which are known. Those papers which report r e la t iv e  p oten cies of a few : 
of these compounds are not always in  agreement (6 1 ,6 2 ,6 3 ) . The d iscrep ­
ancies seem to  be due to  the varied  techniques which are used to  de­
termine an tih istam in ic  p rop erties . No reports have been found which re­
la te  an tih istam in ic  action  or potency, and epinephrine augmenting e f f e c t ,
The Autonomic G anglionic Blocking Action  
of Epinephrine and Norepinephrine 
M arrazzi has stu d ied  the a c tio n  of epinephrine and other 
sympathomimetic amines on transm ission  p rocesses in  sym pathetic ganglia  
(6 4 -7 2 ). His in v e st ig a tio n s  have provided evidence that epinephrine can 
reduce the a c tio n  p o te n tia ls  in  the p o stg a n g lio n ic  f ib e r s  of adrenergic 
nerves fo llow in g  farad ic stim u la tion  of the preganglionic nerves. The 
same phenomenon has a lso  been shown to  occur w ith  ephedrine. In addition  
to  the gan g lion ic  blocking e f f e c t  of ephedrine, h is  s tu d ie s  revea l an
14
increased  p o te n tia l in  preganglionic nerves, in d ica tin g  that perhaps 
ephedrine a c t iv a te s  sympathetic c e l l  bodies in  the cen tra l nervous 
system . Ephedrine, however, appears to have le s s  e f f e c t  as a ganglion ic  
blocker than does epinephrine. The depression of ganglion ic  transm ission  
by epinephrine has been d iscu ssed  by Marrazzi as a mechanism having a !
b e n e f ic ia l  e f f e c t ,  whereby epinephrine can check ex cess iv e  sympathetic 
a c t iv i t y .  In other words, th is  mechanism would afford  the adrenergic |
system  with i t s  own "brake". j
I
BUlbring and Burn found that sm all doses of epinephrine aug- I
mented ganglion ic  transm ission while large doses depressed i t .  They 
th eorized , in  the d iscu ssio n  of th e ir  work, that a decrease of sympa- | 
th e t ic  gan glion ic  transm ission caused by the in fu s io n  of epinephrine 
might w e ll be the cause of the f a l l  in  blood pressure seen follow ing  
c e ssa tio n  of the in fu sion  (7 3 ).
Konzett has reported that norepinephrine produces reduced 
transm ission across the superior c e r v ic a l ganglion  in  the c a t (74 ), 
Lundberg, who used the s t e l la t e  ganglion of the ca t as h is  t e s t  prepa­
ra tio n , concluded that norepinephrine was four tim es le s s  potent than 
epinephrine in  regard to i t s  ganglion ic  blocking e f f e c t  (7 5 ).
The M etabolic E ffe c ts  of Epinephrine and Norepinephrine
Epinephrine has been known, for many y e a r s, to  produce an in ­
crease in  b asa l m etabolic ra te . The work of Goldenberg et a l . , showed 
th at norepinephrine, in  co n tra d is t in c tio n  to ep inephrine, had r e la t iv e ly  
l i t t l e  e f f e c t  on the m etabolic rate  in  man (7 6 ). Most in v e stig a to rs  now 
agree that norepinephrine i s  approximately 5 to  10 times le s s  active
15
than epinephrine in  th is  regard.
Sahyun and Webster, in  th e ir  s tu d ie s  on r a ts , observed that 
norepinephrine tended to cause g lycogen esis  in  the s k e le ta l  muscle w hile ;
I
epinephrine caused g lycogen o lysis  (7 7 ) . From the data compiled by the |
I
many in v e st ig a to r s  who have studied the e f f e c t s  of norepinephrine and | 
epinephrine on g lycogen o lysis  and glyceraia, a l l  authors agree th at the 
action s of norepinephrine are only 1 /5  to 1/10 that of epinephrine.
I
Norepinephrine seems to have a l l  of the m etabolic action s which e p i-  j  
nephrine has, but to a much le s se r  degree. These action s include pro- I  
duction of hyperglycem ia, increase in  blood la c t ic  ac id , decrease in  j  
adrenal ascorbic acid , and decrease in  blood amino acid s.
Prolonged Infusion  of Epinephrine and Norepinephrine 
The l ite r a tu r e  contains many more s tu d ie s  of the long-term  in ­
fu sion  of epinephrine than of norepinephrine.
I
Freeman, Freedman, and M iller  (78) produced shock in  unanesthe* 
t ized  dogs fo llow ing the continuous in fu sion  of 0.0034 to 0.0164 m g .A g ./  
Inin, ep inephrine, continued for 1 to 1 .5  hours. They noted a decrease  
in  plasma volume.
B lacket e t  a l . , infused rab b its  with varying amounts of nor­
epinephrine for  5 to 8 days. They found no s ig n if ic a n t  hemoconcentration
but did find  massive gas pockets in  the in te s t in e s .  They suggested that:
!
the reason for  shock, produced by norepinephrine, was a r e lea se  of some i 
v asod ila tor  substance in to  the c ir c u la t io n  (7 9 ).
i
Vigran and Essex observed shock and death in  dogs who were j  
given large doses of epinephrine by in fu sio n . They came to no conclu sions
16
regarding the mechanism involved (80 ). However, Essex reported in te n s iv e  
c o n str ic t io n  of hepatic v e in s , an increase in  portal venous pressure and 
o cc lu sive  spasm of the secondary branches of the pulmonary a r te r ie s  (8 1 ).
Guyton and G il le s p ie ,  using dogs, reported a decrease in  blood  
volume of 17 per cent during the f i r s t  10 minutes of in fu sion  w ith ep i­
nephrine. However, the blood volume decreased no further during the 
r e s t  of the in fu sio n  (8 2 ) . i
Pekkarinen and H ortling (83) in fused  epinephrine, 0 .2  mcg.Ag.j^  
m in ., in to  human su b jects  for 52 m inutes. Blood s tu d ie s  revealed a 67 
per cent in crease  in  blood sugar, a 33 per cen t increase in  blood la c t ic |
a c id , a 13 per cen t in crease  in  serum c h o le s te r o l ,  and a 22 per cent de-!
I
crease in  serum potassium . j
Muirhead e t  a l .  , reported a decrease in  plasma sodium and an 
increase in  plasma potassium in  dogs fo llow in g  the in fu sio n  of 1 to  7 mg. 
norepinephrineA g. for 20 to  50 m inutes. There were no changes in  plasma 
ch lorid es (8 4 ) . |
Vasodepressor M aterial (VDM) and i t s  R elation  
to  Epinephrine and Norepinephrine 
Chambers e t  a l . ,  found two substances in  the blood of animals 
in  which shock had been induced which they c a lle d  vasopressor and vaso­
depressor m ateria l (8 5 ) . Early in  shock, the blood of the shocked 
animals showed a vasopressor action  on the ra t mesoappendix; la te  in  
shock there was a vasodepressor response, Shorr and h is  co-workers 
found that l iv e r  and s k e le ta l  muscle formed con sid erab le  q u a n titie s  of 
vasodepressor m a ter ia l, but th a t other organs such as cardiac m uscle.
17
smooth m usclé, sp le  eh and kîühëy di^ hot (8 6 ) . Shorr la te r  reported that: 
jthe renal tubules formed vasopressor m a ter ia l, and l iv e r  was the p r in c ip a l 
s i t e  for  the form ation of vasodepressor m ateria l (8 7 ) . Since 1947, Shor::
j
and h is  a s so c ia te s  have published a s e r ie s  of papers supporting the
I
jtheory that vasopressor and vasodepressor m ateria l were regulatory  
hepato-renal fa c to r s  involved in  c ir c u la to r y  hom eostasis.
Mazur and Shorr (88) characterized  hepatic vasodepressor 
m ateria l (VDM) as being id e n t ic a l  w ith f e r r i t in  and a p o fe rr itin . Baez, 
Mazur and Shorr showed a lso  th at f e r r i t in  and vasodepressor m aterial 
were a n tid iu r e t ic  (8 9 ).
I
Baez, Srikantia  and Shorr (90) reported th at D ibenzyline and 
GD-131 were b e n e f ic ia l  in  p ro tec tin g  r a ts  from both traumatic and 
hemorrhagic shock. D ibenzyline i s  an adrenergic b locking agent (9 1 ) .
I
GD-131 i s  s im ila r  to D ibenzyline chem ically  but has l i t t l e  or no adren­
erg ic  blocking a b i l i t y  (9 2 ). Both compounds exh ib ited  a blocking a c tio n  
bn the form ation of vasodepressor m ateria l in  rat l iv e r  in  v itr o .
1 Mazur, Green and Shorr (9 3 ) , and Green, Mazur and Shorr (9 4 ) ,
have reported that Fenton's reagent (Fe^’*’+H202) o x id iz e s  adrenaline to  
adrenochrome at pH 4 .5 . F e r r it in  plus hydrogen peroxide a lso  c a ta ly zes
jthe oxidation  of adrenaline to  adrenochrome. The iron  u t i l iz e d  in  th is
!
p rocess i s  only a fra c tio n  of the t o t a l  iron  found in  f e r r it in .
S h orr's fin d in gs that vasodepressor m ateria l i s  formed most 
r ea d ily  in  the l iv e r  fo llow in g  marked ischem ia of the organ have pro­
vided  evidence th at VDM might be a fa c to r  in  the depressor a f te r e f f e c t s  
iof norepinephrine. Norepinephrine has been shown to cause m assive
C on str ic tion  of hepatic- v e s s e ls  ( 8T) . — T his-cou ld—lead—to-h ep atic-----------
ischem ia and form ation of VDM.
CHAPTER II I  
PROCEDURES
Mongrel dogs were an esth etized  with pentobarbital sodium 
(30 m g.A g. I .V .) follow ed by doses of 3 m g.A g. as was necessary to  
m aintain the desired  degree of an esth esia . The femoral ve in  was cannu- 
la ted  w ith  polyethylene tubing. The tubing was attached to  a Luer-Lok- 
iCoupler which adapts to  any standard syringe. A syringe f i l l e d  with  
sa lin e  was in ser ted  in to  the coupler. In jec tio n s  of the various drugs 
used were made through th is  tubing and then washed in  with a few ml. of 
|sa lin e . The trachea was cannulated to  m aintain an open airway and to  
f a c i l i t a t e  the use of a resp ira tio n  pump i f  necessary. The r igh t  
jcarotid artery  was cannulated and the blood pressure recorded using a 
mercury manometer (capable of recording 350 mm, Hg.) attached to the 
cannula by means of heavy w all rubber tubing. The recording system was 
f i l l e d  w ith  10 per cent sodium c it r a te  to  in h ib it  c lo t t in g . For long­
term experim ents, 3 to  10 mg. of heparin were g iven  I .V . , depending upon 
the s iz e  of the animal, as an a d d itio n a l precautionary measure to  prevent 
c lo t t in g  in  the cannula.
In the experiments which involved vagal stim u la tio n , the r ig h t  
vagus was section ed  and a sh ield ed  e lectrod e  was attached to  the nerve 
d is ta l  to  the point of se c tio n . Square wave stim u la tion  was accomplished
18
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by an American El e c tr ie  Laboratory Model 751 E lectron ic  Stim ulator.
i
j For long-term in fu sion  experim ents, a constant rate in fu sio n
apparatus (95) (F ig . 1 ) , using a 100 cc . syr in ge , was attached to the 
cannula in  the femoral ve in . The syringe was f i l l e d  w ith the desired  
pmount of norepinephrine in  iso to n ic  sa lin e  and the apparatus adjusted  
for the desired  rate of in fu sion .
I  Glucose was determined in  the venous blood, in  some experiments
by the micro-method of Horvath and Knehr (9 6 ) , using a Bausch and Lomb 
l^pectronic 20 Colorim eter.
I Some experiments were designed to t e s t  the augmenting action
I
of ephedrine and ce r ta in  an tih istam in ics on the pressor response to
!
s in g le  doses of norepinephrine or epinephrine. Since n eith er  height nor 
duration of the pressor response were considered to be dependable in d ices  
of augmentation, a planimeter was employed to  determine the area under 
|the blood pressure curves. Thus, a r a tio  was esta b lish ed  between the 
pressor response to an in je c t io n  of norepinephrine or epinephrine, befor« 
and a fter  the in je c t io n  of the augmenting agent.
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CHAPTER IV
EXPERIMENTS AND DISCUSSION
The E ffe c ts  of Continuous Intravenous In fu sion  of Norepinephrine
S ix  dogs were prepared to  record blood pressure as described  
in  Chapter I I I .  Blood pressure was recorded u n t i l  i t  a tta in ed  a s ta b le  
le v e l  and then con stan t-ra te  in fu sio n  of norepinephrine was s ta r te d .
[Two animals were given  by intravenous in fu sio n  a t o t a l  dose of 0 .5  mg. A
|of norepinephrine over a period of 5 hours. Three animals were in fused
I
with increasing doses of norepinephrine each hour for 4 hours: 0 .1  mg./
kg. norepinephrine was infused during the f i r s t  hour; 0.15 m g.A g ., the
second hour; 0.20  m g .A g . , the third hour; and 0 .25  m g.A g ., the fourth
i
hour. One animal was in fused  with 1 m g.A g. in  5 hours.
i These experiments were designed as co n tro ls  for ensuing exp er i-
I
meats and to  determine whether the card iovascu lar response would be 
markedly d if fe r e n t  by using d iffe r e n t  dosage regimens.
These experim ents pointed out two main fa c t s  concerning the 
card iovascu lar response to  con stan t-ra te  in fu sio n  of large amounts of
I
horepinephrine regard less of the regimen used. F ir s t ,  during the early
minutes of in fu s io n  the blood pressure r is e s  p r e c ip ito u s ly , and then
!
f a l l s  gradually to  or below p r e -in fu sio n  le v e ls .  Second, the blood
I
p re.ssu re_fa lls  p r e c ip ito u sly  a t  the -conclusion  o f-an  in fu sio n . Following
21
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th is  f  a l l ,  the blood pressure may" remain r e la t iv e ly  stab le  a t  th is  hypo­
ten sive  le v e l  (Table I: Dogs 3, 4 , 13); i t  may slow ly climb toward the 
Di’C -infusion le v e l  (Table I: Dogs 2 , 12); or i t  may f a l l  to  zero with  
lea th  r e su lt in g  (Table I: Dog 1).
!
j O bservation revealed other c o n s is te n t e f f e c t s .  These animals
had episodes of paroxysmal h y p erven tila tion . Heart rates were extremely 
[r ira tic , ranging from marked tachycardia to  severe bradycardia. "Gallop
I
Lhythm" and other arrhythmias were m anifest in  th ese  experim ents. Most
j
Jof the animals sa liv a ted  profusely .
General fin d in gs a t autopsy showed by gross in sp ection  
ischemic v isc e r a , acute passive congestion  of the l iv e r ,  edema of lungs 
and lim bs, and d is te n tio n  of the stomach by gas. The lungs of most of 
the animals d isp layed  recent fo c a l hemorrhages.
F ig . 2 (Dog 12, Table I) i s  a ty p ic a l example of those 
experiments in  which the in fu sio n  dose of norepinephrine was increased
j
by a fix ed  increment each hour during the in fu sio n . At the beginning  
of the in fu sion  the blood pressure rose d ram atica lly . This r is e  was 
accompanied by a marked bradycardia, probably vagal in  o r ig in . Within 
f iv e  minutes the blood pressure began to  drop and the heart rate changed 
toward the con tro l-p eriod  le v e l .  At the end of each hour, during the 
time in  which the syringe was being f i l l e d  with norepinephrine at the 
new dosage le v e l ,  the blood pressure dropped markedly. When the
I
in fu sion  was resumed, the same cyc le  recurred,
i
F ig . 3 (Dog 13, Table I) i s  an example of those experiments 
in  which a s in g le  dose le v e l  of norepinephrine was infused at a constant 
ralje_fjar_five_succ.essjLv,e_hours_wi±liout-Stopping*.. l±_.can_be._seen-tha.t___
TABLE I 1
CONTROL INFUSION EXPERIMENTS !
DOG-SEX-WEIGHT DOSE OF MEAN BLOOD HIESSURE IN MM. HG.
NOREPINEPHRINE PRE-INFUSION 3 MIN. POST-INFUSION 1 m .  POST-INFUSION REMARKS
l-raale-13.6 kg. 0.5 mg. /kg. /5 hrs. 160 108 0 died 1 hr. 
post­
infusion
2-male-10 kg. 0.5 rag./kg./5 hrs. 146 70 110 killed 1 nr. 
48 rain, post­
infusion;
B. P. 114
3-male-6.8 kg.
j
0.1 mg./kg.,1st hr. 
0.15 mg./kg.,2nd hr. 
0.20 mg.Ag. ,3rd hr. 
0.25 mg.Ag.,4th hr.
138 46 30 killed 1 nr, 
10 rain, 
post-infusion 
B. P. 30
|4-male-7.3 kg. same as dog 3 150 68 60 killed 1 hr. 
5 rain, post­
infusion;
B. P. 60
12-female-9 kg. same as dog 3 114 40 64 killed 1 nr. 
32 rain, post­
infusion;
B. P. 72
13-female-7 kg. 1 mg . Ag./5 hrs. 140 66 56 killed 1 nr. 
39 rain, post- 
infusion;
B, P. 64
female-24 kg. 30 mg./21 hrs. 15 rain. — — — 1
See Fig. 4 and text j
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F ig . 2
Dog 12 Upper Marker: 0 Blood Pressure
Female 9 kg. Lower Marker: Time: 10 seconds
1. Norepinephrine 10 meg, I.V .
2. Kymograph: stopped.
3. Norepinephrine 0 .1  m g .A g ./h r . I . V. in fu sio n  s ta r te d .
4. Kymograph: 1 min. on, 10 min. o f f .
5. Norepinephrine 0 .1  m g .A g .A r . I . V. in fu sio n  stopped.
6. Norepinephrine 0 .15 m g .A g .A r . I . V. in fu sio n  s ta r te d .
7. Kymograph: 1 min. on, 10 min. o f f .
8. Norepinephrine 0 .15  m g .A g .A r . I .  V. in fu sio n  stopped.
9. Norepinephrine 0 .2  m g .A g .A r . I . V. in fu sio n  r ta r ted .
10. Kymograph: 1 min. on, 10 min. o f f .
11. Norepinephrine 0 .2  m g .A g .A r . I . V. in fu sio n  stopped.
12. Norepinephrine 0 .25  m g .A g .A r . I . V. in fu sio n  s ta r te d .
13. Kymograph: 1 min. on, 10 min. o f f .
14. Norepinephrine 0 .25  m g .A g .A r . I . V. in fu sion  stopped.
15. Kymograph: 1 min. on, 10 min. o f f .
16. K illed  animal w ith  ether I .  V.
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F ig . 3
Dog 13 Upper Marker: 0 Blood Pressure
Female 7 kg. Lower Marker: Time: 10 seconds
1. Norepinephrine 1.0 rag./kg./5  hrs. I .  V. in fu sion  sta r ted .
2. Kymograph: 1 rain, on, 10 min. o f f .
3. Norepinephrine 1,0 m g ./k g ./5  hrs. I .  V. in fu sio n  stopped.
4. Kymograph: 1 min. on, 10 min. o f f .
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e s s e n t ia l ly  the same phenomenon occurred as was seen in  Fig. 2.
F ig . 4 (Dog * , Table I) shows a record taken in  one of s ix  
Experiments in  which the animals were su bjected  to  an in fu sio n  of nor­
epinephrine at a dose and rate necessary to  keep the blood pressure e l e -  
\'ated (9 5 ). A ll of these animals d ied  during in fu sio n s  which la sted  
from 14 to  21+ hours. The record i l lu s t r a t e s  the fa c t  that as the experi 
ment progressed the rate of in fu sio n  had to  be increased in  order to  
keep the blood pressure e levated . A second p o in t to  be noted i s  that at 
The beginning of each 2 mg. dose of norepinephrine the blood pressure  
atta in ed  q u ite  high le v e ls  but gradually lowered even though the in ­
fu sion  was proceeding at a constant ra te . These experiments in d ica te  
that there i s  a p ro g ressiv e ly  decreasing card iovascu lar response to  nor­
epinephrine given  over a long period of tim e.
The E ffec ts  of D ibenzyline and GD-131 
These experiments were designed to  determine whether vaso­
depressor m ateria l (VDM) might be a con trib u tin g  factor  in  producing the 
T ^asodepressor-aftereffect of norepinephrine. S ince the m aterials  
necessary to  determine VDM in  l iv e r  were not a v a ila b le , i t  was decided  
tjo in v e s t ig a te  the matter pharm acologically using Dibenzyline and GD-131.
i
The r a tio n a le  concerned w ith the use of th ese  drugs in  the a n a ly s is  of 
th is  fa cto r  has been d iscu ssed  in  Chapter I I ,  page 17.
C ontrol experiments were performed to  determine the amount of 
ib en zy lin e  necessary to  block the pressor e f f e c t  of a given dose of nor 
epinephrine and epinephrine. I t  was found th at 5 m g.A g. of D ibenzyline  
wbuld block the pressor response to  epinephrine but 10-15 m g.A g. were
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necessary to  b lock that of norepinephrine. A d istu rb in g  feature Was 
jthat D ibenzyline at these dose le v e ls  produced hypotension. Fig, 5 
(Dog 6 , Table I I )  shows that D ibenzyline produced reversa l of the presso  
leffect of epinephrine and norepinephrine. "Epinephrine reversal"  i s  a 
Well known phenomenon. However, norepinephrine rev ersa l i s  not w e ll  
recognized. The theory o f th is  phenomenon i s  th at adrenergic blocking  
iagents in h ib it  the pressor e f f e c t  (v a so co n str ic to r  action ) but do not 
in h ib it  the depressor e f f e c t  (v a so d ila to r  action ) of epinephrine. Nor­
epinephrine, according to most in v e s t ig a to r s , i s  supposed to  be purely 
^vasoconstrictor and to have l i t t l e ,  i f  any, vasod ila tor  p rop erties . 
Nickerson, Henry and Nomaguchi (92) have reported that norepinephrine 
does have a s l i g h t  depressor e f f e c t  in  c a t s ,  fo llow in g  D ibenzyline in  
doses of 2-5 m g.A g.
F ig . 6 (Dog 7 , Table I I )  i s  the record of an experiment which 
shows the e f f e c t  of con stan t-ra te  in fu sio n  of norepinephrine fo llow ing  
D ibenzyline. The pressor e f f e c t  of norepinephrine was almost com pletely  
blocked and the reversa l (depressor e f f e c t )  was so  pronounced that i t  
led  to  the death o f the animal.
I t  soon became evident that th is  method could not be used to  
protect aga in st the norepinephrine depressor e f f e c t  because i t  a c tu a lly  
(Complemented the hypotension. I t  d id , however, make c lea r  that norepi­
nephrine i s  not a pure vasocon str ictor  agent. This adds support to  the 
!
growing opinion th at norepinephrine i s  not as d if fe r e n t  q u a lita t iv e ly  
from epinephrine as many in v e stig a to r s  have in d ica ted . For many years 
c lin ic ia n s  have been warned aga inst the use of epinephrine in  combating 
i îh o ck -sta t^  -because- of—its -a b iT ify -  to  s e n s it iz e  heart muscle^ and fh e —
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TABLE II  
DIBENZYLINE EXPERIMENTS
Dog 5~m ale-12.3 kg.
D ibenzy line; 15 mg.Ag. I . V. in  d ivided  d o ses , in  40 minute 
period.
Norepinephrine; 20 meg. I . V. as s in g le  in je c t io n s .
Epinephrine; 20 meg. I . V. as s in g le  in je c t io n s .
Remarks ; Norepinephrine and epinephrine rev ersa l. Normal B, P.
110 mm. H g.; a t end of experiment B. P. 36 mm. Hg.
Dog 6-m ale-7 kg.
D iben zy lin e; 10 mg.Ag. I . V. in  d ivided d o ses , in  29 minute 
period.
I Norepinephrine; 7 meg. I . V. as s in g le  in je c t io n s .
Epinephrine; 7 meg. I . V. as s in g le  in je c t io n s .
Remarks ; Norepinephrine and epinephrine rev er sa l. Normal B, P.
120 mm. H g.; a t end of experiment B. P. 54 mm. Hg.
Dog 7-fem ale-9 kg.
D ibenzy line: 10 m g.A g. I . V. in  d ivided  d o ses , in  25 minute
period .
Norepinephrine; In fu sion
0 .1  m g .A g ., 1st hour
0.25 m g .A g ., 2nd hour
0.25 m g .A g ., 3rd hour
Remarks ; Animal died 43 minutes in  3rd hour of in fu sio n .
Norepinephrine reversa l from the s ta r t  of in fu sio n .
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TABLE II  ( con t . )
DIBENZYLINE EXPERIMENTS
[Dog 8-m ale-6 .4  kg.
D ibenzy line; 5 mg.Ag. I . V.
j
Norepinephrine ; Infusion  
I 0 .1  mg.Ag. , 1st hour
0.15 m g.A g., 2nd hour 
I 0 .20 m g.A g., 3rd hour
! 0.25 m g.A g., 4th hour
!
I Remarks: Normal B. P. 104 mm. Hg. ; a fte r  D ibenzyline B. P.
I 30 mm. Hg. Wyamine 50^ (1 m g.A g. I . V.) was given
i  before and a fte r  D ibenzyline. The pressor action  of
! Wyamine was dim inished by D ibenzyline. Norepinephrine
I in fu sio n  did not e le v a te  B. P. above 30 mm. Hg.
I Dog 9-male-lO kg.
I  D iben zylin e: 10 mg.Ag. I . V. in  divided d o ses , in  20 minute
j period.
1 Norepinephrine; Infusion
1 0 .1  mg.Ag. , 1 st hour
! 0.15 mg.Ag. , 2nd hour
; 0.20 m g.A g., 3rd hour
i Remarks : Normal B. P. 140 mm. H g.; a fte r  D ibenzyline B. P.
76 mm. Hg. The animal died 13 minutes in  3rd hour
of in fu sio n .
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F ig. 5
Dog 6
Male 7 kg. Upper Marker: 0 Blood Pressure
Lower Marker: Time: 10 seconds
3. Norepinephrine 7 meg. I . V.
4. Epinephrine 7 meg. I . V.
5. 6 , 7 , D ibenzyline 10 meg. I . V.
Total dose was 70 mg. or 10 mg.Ag. Record does not 
show to ta l  amount adm inistered.
16. Norepinephrine 7 meg. I . V.
17. Kymograph: o ff
18. Epinephrine 7 meg. I . V.
19. Kymograph: 1 min. on, 10 min. o ff .
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Fig. 6
Dog 7 Upper Marker: 0 blood pressure
Female 9 kg. Lower Marker: Time: 10 seconds
1. Norepinephrine 20 meg. I . V.
2. D ibenzyline 5 m g.A g. I .  V.
3. Kymograph: 1 min. on, 10 min. o f f .
4. D ibenzyline 5 m g.A g. I . V.
5. Norepinephrine 20 meg. I . V.
6. Started  con stan t rate in je c t io n  machine.
7. Norepinephrine 0 .1  m g .A g .A r . I . V. in fu sio n  s ta r ted .
8. Kymograph; 1 min. on, 10 min. o f f .
9. Norepinephrine 0 .1  m g .A g .A r . I. V. in fu sio n  stopped.
10. Norepinephrine 0.25 m g .A g .A r . I . V. in fu sio n  sta r ted .
11. Kymograph; 1 min. on, 10 min. o f f .
12. Norepinephrine 0 .25  m g .A g .A r . I . V. in fu sio n  sta r ted ,
13. Norepinephrine 0 .25 m g .A g .A r . I . V. in fu sio n  sta r ted . 
Animal d ied  43 minutes la te r .
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vasodepressor component of i t s  ac tion . The argument has been that during 
shock, normal r e f le x  mechanisms promote v a so co n str ic tio n  and tachycardia; 
th erefore , epinephrine would not be in d ica ted . In ad d ition , there was 
|some concern that the vasodepressor e f f e c t  would p e r s is t  a fter  d is ­
continuing epinephrine and thus augment an already hypotensive s ta te .  
Norepinephrine, on the other hand, has been denoted as having l i t t l e  
{effect on cardiac s e n s i t iv i t y  or r a te , and l i t t l e  vasod ila tor  a c tio n . 
These experiments in d ica te  that norepinephrine can cause tachycardia, 
arrhythmias and vasodepression , although the dose of norepinephrine 
necessary to  produce chese phenomena i s  much higher than that of ep i­
nephrine.
GD-131, at a dose le v e l  of 10 m g.Ag. I . V ., produced some 
blocking e f f e c t  on the pressor response of norepinephrine, F ig . 7 
fDog 10, Table I I I ) .  I t  did not reverse the e f f e c t  of norepinephrine as 
did D ibenzyline at the same dose le v e l .  I t  did not protect aga in st the 
p o st-in fu sio n  hypotension, and the animal died as did some of the contro l 
animals.
F ig . 8 (Dog 11, Table I I I )  shows the e f f e c t s  of GD-131 
|(1 mg.Ag. I . V .) g iven  before norepinephrine in fu sio n . The r e su lts  are 
bot m ater ia lly  d ifferen t from those seen in  the con tro l experim ent,
j
Pig. 2.
The record of Dog 14, Table I I I ,  was very sim ilar to the 
control experiment pictured in  F ig. 3. In th is  experiment the dose of 
GD-131 was 5 m g.A g. I . V. follow ed by an in fu sio n  (1 m g .A g ./5  h r s .)  of 
norepinephrine.
— These experiments tend to in d ica te  that GD-T3T does not protect^
DOG-SEX-WEIGHT DOSE OF GD-131
TABLE III 
GD-131 EXPERIMENTS
DOSE OF NOREPINEPHRINE
j
i
j
1
REMARKS
INFUSION
lO-female-8 kg. 10 mg.Ag. I. V. 
in divided doses, 
in 5 rain.
0.1 mg.Ag. 1st hour 
0.15 mg.Ag. 2nd hour 
0.20 mg.Ag. 3rd hour 
0.25 mg.Ag. 4th hour
B. P. 120 before GD-131; B. P. 122 before 
infusion with norepinephrine B. P. 120 
at point of end of infusion. Dog died 
1 hr. 37 min. following end of infusion.
|ll-female-6 kg. 1 rag. Ag. I. V. same as dog 10 Record not significantly different from 
control animals. B. P. fall after each 
dose. Pre-infusion B. P. 114; B. P. 100; 
2 hrs. 20 min. post-infusion when killed.
;I4-raale-10 kg. 5 mg.Ag. I. V. 1 mg. Ag. /5 hrs. Pre-infusion B. P. 112; B. P. 48,
1 hr. 49 min. post-infusion when killed. ;
COvO
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Fig. 7
Dog 10 Upper Marker: 0 blood pressure
Female 8 kg. Lower Marker: Time: 30 seconds
1. Norepinephrine 10 meg. I . V,
2. Kymograph: o f f .
3. Norepinephrine 10 meg. I . V.
4. Kymograph: o f f .
5. GD-131 5 m g.A g. I . V.
6. GD-131 5 m g.A g. I . V.
6A. Kymograph: 1 min. on, 10 min. o f f .
7. Norepinephrine 10 meg. I . v.
9. Not shown, Norepinephrine 0 .1/mg. A g . A r . I . V. in fu sion  s ta r ted .
10. Norepinephrine 0 .1  m g .A g .A r . I . V. in fu sio n  stopped.
11. Norepinephrine 0 .15 m g .A g .A r . I . V. in fu sio n  s ta r ted .
12. Kymograph: 1 min. on, 10 min. o f f .
13. Norepinephrine 0 .15  m g ./k g .A r . I . V. in fu sion  stopped.
14. Norepinephrine 0 .2  ir g ./k g .A r . I . V. in fu sion  s ta r ted .
18. Kymograph: 1 min. on, 10 min. o f f .
19. Norepinephrine 0 .25  m g .A g .A r . I . V, in fu sio n  stopped.
20. Kymograph: 1 min. on, 5 min. o f f .
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Fig. 8
Dog 11 Upper Marker: 0 blood pressure
Female 6 kg. Lower Marker: Time: 10 seconds
1. Norepinephrine 10 meg. I . V.
2. GD-131 1 m g.A g. I .  V.
3. Kymograph: o f f .
4. Nembutal 30 mg. I . V.
5. Norepinephrine 0 .1  m g .A g .A r . I . V. in fu sio n  s ta r te d .
6. Kymograph: 1 rain, on, 10 min. o f f .
7. Norepinephrine 0 .1  m g .A g .A r . I . V. in fu sion  stopped.
8. Norepinephrine 0 .15 m g .A g .A r . I . V. in fu sion  s ta r ted .
9. Kymograph; 1 min. on, 10 min. o f f .
14. Norepinephrine 0 .25 m g .A g .A r . I . V. in fu sion  s ta r te d .
15. Kymograph: 1 min. on, 10 min. o f f .
16. Norepinephrine 0 .25 m g .A g .A r . I . V. in fu sion  stopped.
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^against the depressor a f te r e f f e c t  of norepinephrine.
Experiments on the G anglionic Blocking E ffect of Norepinephrine
As sta ted  in Chapter I I ,  page 13, epinephrine and norepinephrine 
have been found to  produce some degree of ganglion ic blockade in  the 
superior c e rv ic a l and s t e l la t e  ganglia of the ca t. G anglionic blockade 
causes marked hypotension because of in h ib it io n  of the normal passage of 
im pulses to  postganglion ic autonomic nerves. Adrenergic nerves provide 
for the general tonus of peripheral blood v e s se ls  and s t a b i l iz e  peripheral 
resis ta n ce  and blood pressure. I f  blood v e sse l tonus i s  reduced by 
gan g lion ic  blockade, peripheral v a so d ila tio n  ensues, peripheral re -
I
s is ta n c e  i s  lowered, and the r esu lt  i s  hypotension or shock.
; The aim of these experiments was to  determine i f  ganglion ic
blockade was present both during and fo llow in g  in fu sion  with norepi­
nephrine (1  m g .A g ./5  h r s .) .
Vagal stim u lation  was chosen as a means of studying ganglion ic
|transm ission. There i s  ample evidence in  the lite r a tu r e  that para-
I
sym pathetic ganglia  react m ateria lly  the same as sympathetic gan g lia .
I t  was f e l t ,  therefore, that fa ilu r e  of the blood pressure to  decrease  
<as a response to vagal stim u la tion  would in d ica te  vagal gan glion ic  
blockade. I t  must be recognized that the e f f e c t s  of vagal stim u la tion
i
might be somewhat dim inished by the p o s it iv e  chronotropic and in otrop ic  
e f f e c t s  of norepinephrine on the myocardium. Thus, a decrease in  the 
blood-pressure-low ering e f f e c t  of vagal stim ulation  would not n e c e ssa r ily  
denote gan g lion ic  blockade. However, any drop in  blood pressure obtained 
by vagal stim u la tion  would tend to su b stan tia te  the absence o f blockade
46
îsince vagal action  i s  opposed by the e f f e c t  of norepinephrine on the 
jsympathetic innervation  of the heart.
Pour animals were prepared for these experiments as d iscussed  
in  Chapter I I I .  Vagal stim u lation  was accomplished by using a 6 v o lt ,
60 im p u ls e s /s e c ., 10 m illisecon d  duration square wave stim u lation . A 
vagal s tim u la tio n  of 2 to  3 seconds was found adequate to  produce a f a l l  
in  blood pressure of 40 to 100 mm. Hg. prior to in fu sio n . Vagal stimu­
la t io n  was then repeated each hour during and fo llow ing in fu sio n . 
A cety lch o lin e  (10 meg. I . V .) was g iven  before and follow ing the end of 
in fu sio n . This provided a means of determ ining the a b il i ty  of the anima 
ito react to  vagal stim u la tion . As in  the con tro l experiments the blood 
pressure gradually f e l l  w hile the in fu sio n  progressed. The p o s s ib i l i ty  
I of obtaining a decreased response to  vagal stim u la tion  under these  
circum stances i s  qu ite evident because i t  i s  d i f f i c u l t  to  further depres 
an a ctio n  which i s  already depressed or stim u la te  one which i s  already 
stim ulated . Therefore, the adm in istration  of a ce ty lch o lin e  a lso  provided 
an in d ica tio n  of the a b i l i t y  of the animal to  respond to  a depressor 
in flu en ce  when the blood pressure was depressed.
F ig . 9 (Dog 16) shows that the perip hera l ganglia of the vagus 
were function ing both during and fo llow in g  in fu s io n , sin ce  a f a l l  in  
blood pressure was e l i c i t e d  by vagal stim u la tion  throughout the experi­
ment. One animal (Dog 17) showed some vagal block but a lso  lacked the 
a b i l i t y  to  react very stron g ly  to a c e ty lc h o lin e . The in ta c t  vagus was 
stim ulated in  Dog 18 and the blood pressure was recorded from the r igh t  
femoral artery . This was done in  order to  keep caro tid  r e fle x e s  in ta c t .  
An adequate response to vagal stim u la tion  was accomplished by stimulatin{g
47
Fig. 9
Dog 16 Upper Marker: 0 blood pressure
Female 6 .4  kg. Lower Marker: Time: 10 seconds
2. Vagal s tim ula tion .
3. Vagal s t im ula t ion .
4. A cety lcholine 10 meg. I , V.
5. Norepinephrine 1 m g .A g ./5  hrs. I . V. in fu s ion  s tar ted .
6 . Kymograph: 1 min. on, 15 min. o f f
7. Vagal s t im ula t ion .
14. Vagal s t im u la t io n  4 hrs. a f te r  in fu sion  started .
15. Kymograph: 1 min. on, 15 min. o f f .
16. Vagal s tim u la t ion  4 hrs. 55 min. a f te r  in fu sion  s tarted .
17. Norepinephrine 1 m g .A g ./5  hrs. I .  V. in fu sion  stopped.
18. Vagal s tim ulation .
19. Vagal s tim ula t ion .
20. A cety lcholine 10 meg. I. V.
21. Dog k i l l e d  with ether I. V.
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for 5 seconds and advancing square wave duration to  20 m illisecond s. In ; 
th is  experiment the response to stim ulation  was diminished during in -  i 
fu s ion . The animal died 12 minutes fo llow ing the end of the infusion .  
Autopsy revealed massive pulmonary hemorrhage which was thought to be 
the immediate cause of death, j
: i
I t  i s  concluded from these experiments that ganglionic blockade
I
i s  not a major factor in  the production of the vasodepressor a f t e r e f f e c t s  
of norepinephrine, }
The E ffec t  of Norepinephrine on Blood Glucose 
Blood glucose was determined in  Dogs 12 and 13 (xable I) and 
Dogs 11 and 14 (Table I I I ) ,  A control sample of blood was c o l le c te d  
before in fu sion . Blood samples were then taken each hour during in ­
fusion , The contro l blood glucose values ranged from 44,4 to 55 ,6  lug, 
per cen t .  The samples taken at the end of each in fu sion  ranged from 
60,8 to  89.6 mg, per cent. In every instance the blood glucose le v e l  
at the completion of in fu sion  was w e ll  above control le v e ls .  Dog 11 
(F ig , 8 ) was given 100 cc. of 5 per cent glucose intravenously a f ter  
the in fu sion  of norepinephrine was completed. I t  did not m ateria lly  
a l te r  the blood pressure of the animal.
In conclusion, norepinepnrine in  the amount given causes a 
moderate degree of hyperglycemia with no evidence of hypoglycemia.
The E ffec ts  of Ephedrine and Antihistamines  
on Norepinephrine and Epinephrine  
In preliminary experiments an attempt was made to determine 
the c a tech o l  amine concentrations in  the blood of dogs receiving
50
norepinephrine by continuous in fu sion . The fluorophotometer (K lett)  
a v a i la b le ,  contains barrier»layer p hotoce lls  and was found to  have in­
s u f f i c i e n t  s e n s i t i v i t y  to determine ca techo l amine concentrations under i
i  i
the conditions of the Weil-Malherbe and Bone method. Therefore, th is  | 
work was not further pursued.
Since ca tech o l  amine determinations could not be made, i t  was 
decided to  explore the d estruct ion  of norepinephrine by amine oxidase. 
This was done by administering a dose of norepinephrine to  a dog and 
observing the e f f e c t  on the blood pressure. An amine oxidase in h ib itor  
was then given and when the blood pressure had s ta b i l iz e d  the or ig in a l  
dose of norepinephrine was repeated, A r i s e  in  blood pressure greater  
than the o r ig in a l  was considered in d ica t iv e  of amine oxidase in h ib it io n  
and a decrease in  destruction  of norepinephrine.
Animals 19, 20 and 21 (Table IV) were given the same pressor  
dose of norepinephrine before and follow ing the adm inistration of a dose 
of ephedrine s u l fa t e  (0 .05  m g.A g. I .  V .) .  A l l  three of the animals 
showed an increased blood pressure response to  norepinephrine following  
the ephedrine. The animals were then in fu sed  with norepinephrine 
(1 m g .A g ./5  h r s . ) .  At the end of each hour during the in fu sion ,
0.05 m g.Ag. of ephedrine was g iven  in travenously . F ig . 10 (Dog 19, 
Table IV) shows that ephedrine given during the in fu sion  augments the 
e f f e c t  of norepinephrine as ind icated  by an immediate r i s e  in  pressure  
which i s  a much greater pressor e f f e c t  than that obtained before in­
fusion  by the same dose of ephedrine. This e f f e c t  was reproduced in  
a l l  three animals te s te d  although the augmentation diminished somewhat 
m t h  time. _The end r e su lt  of norepinephrine, intusion^was not. changed-...
TABLE IV
AUGMENTATION OF NOREPINEPHRINE AND EPINEPHRINE
l)og-Sex-Wt. Augmenting Dose of Nor­ Dose of Area in Area in Ratio
Drug and Dose epinephrine Epinephrine Sq. In. Sq. In. Af ter/Eef
Bef ore After
Augmenter Augmenter
L9-male-ll kg. EPHEDRINE SO4  
0.05 mg./kg. I.V.
20 meg. I.V. 1.030 1.290 1.252
20-male-9 kg. EPHEDRINE SO4 10 meg. I.V. 0.715 0.925 1.294
0.05 mg./kg. I.V.
2 1 -male- 8  kg.
i
EHŒDRINE SO4  
0.05 1% . /kg. I.V.
10 meg. I.V. 0.320 0.565 1.766
23-male-lO.9 kg.
I
PYRIBENZAMINE 
1 mg./kg. I.V.
10 meg. I.V. 0.400 1.410 3.525
34-male- 8  kg. PYRIBENZAMINE 10 meg. I.V. 0.440 0.990 2.250
1 mg. /kg. I.V. 0.1 meg. I.V. 0.030 0 . 0 2 0 0.667
1 0 meg. I.V. 0.250 0.510 2.040
;J5-male-6.4 kg. PYRIBENZAMINE 10 meg. I.V. 0.570 2.890 5.070
1 mg. /kg. I.V. 0.1 meg. I.V. 0.040 0.030 0.750
1 0 meg. I.V. 0.170 0.800 4.706
24-male-10 kg. PYRIBENZAMINE 10 meg. I.V. 0 . 2 1 0 1.815 8.643
0.5 mg./kg. I.V. 10 meg. I.V. 0.285 1.815 6 . 368
1 0 meg. I.V. 0.105 0.540 5.143
1 0 meg. I.V. 0.105 0.540 5.143
27—male-12 kg. PYRIBENZAMINE 10 meg. I.V. 0.180 0.430 2.389
0.5 mg./kg. I.V. 1 0 meg. I.V. 0 . 1 0 0 0.250 2.500
i 0.5 mg./kg. I.V. , 10 meg. I.V. 0 . 2 0 0 0.520 2.600
! 1 hr. after 1 0 meg. I.V. 0 . 180 0.190 1.056
initial dose
25-male-12 kg. TRIMETON 10 meg. I.V. 0. 345 0.650 1.884
.. 0.5 mg. /kg.__.X_V -1 0 --meg.-JU-V_ CU-090___ 0 ^ 2 1 0---- ---- 2.-333
TABLE IV c o n t .
AUGMENTATION OF NOREPINEPHRINE AND EPINEPHRINE
l)og-Sex-Wt. Augmenting Dose of Nor- Dose of Area in Area in Ratio
Drug and Dose epinephrine Epinephrine Sq. In. Sq. In. Af ter/Bef ore
Bef ore Af ter
Augmenter Augmenter
1
26-male-8.6 kg. TRIMETON 1 0 meg. I.V. 0.860 0.890 1.035
0.5 mg./kg. I.V. 1 0 meg. I.V. 0.055 0.185 3.364
;î8 -male- 1 2  kg. BENADRYL 1 0 meg. I.V. 0,190 0.190 1 . 0 0 0
0.5 mg./kg. I.V. 1 0  meg. I.V. 0 . 1 1 0 0 . 1 0 0 0.909
0.5 mg. Ag. I.V. , 1 0 meg. I.V. 0 , 2 0 0 0. 300 1,500
1 hr. after 1 0  meg. I.V. 0 . 2 1 0 0 . 2 0 0 0,952
initial dose
29-female-12 kg. BENADRYL 1 0 meg. I.V. 0.360 0.630 1,750
0.5 mg.Ag. I.V. 1 0  meg. I.V. 0.080 0.090 1.125
0.5 mg. Ag. I.V. , 1 0 meg. I.V. 0.410 0.350 0.854
1 hr. after 1 0  meg. I.V. 0.050 0.070 1.400
initial dose
2 2 -male-ll kg. BENADRYL 1 0 meg. I.V. 0 . 1 2 0 0. 315 2. 625
1 mg. Ag. I.V.
:i0 -male- 1 0  kg. THEPHORIN 1 0 meg. I.V. 1.670 0.660 0.985
0.5 mg. Ag. I.V. 1 0  meg. I.V. 1.180 0 . 2 1 0 1. 167
0.5 mg. Ag. I.V. , 1 0 meg. I.V. 1.900 0,550 0.611
1 hr. after 1 0  meg. I.V. 0.240 0. 140 0.583
initial dose
;!l-male-9.5 kg. THEPHORIN 1 0 meg. I.V. 0.530 0.420 0.792
0.5 mg./kg. I.V. 1 0  meg. I.V. 0.080 0.030 0.375
0.5 mg./kg. I.V. , 1 0 meg. I.V. 0.420 0.170 0.405
1 hr. after 1 0  meg. I.V. 0.050 0.040 0.800
initial dose
CO
TABUE IV  c o n t .
AUGMENTATION OF NOREPINEPHRINE AND EPINEPHRINE
Dog-Sex-Wt. Augmenting 
Drug and Dose
Dose of Nor­
epinephrine
Dose of 
Epinephrine
Area in Area in
Sq. In. Sq. In.
Before After 
Augmentor Augmenter
Ratio
After/Before
32-male-10.9 kg. ANTISTINE 
0.5 mg. /kg. I.V. 
0.5 mg./kg. I.V. , 
1 hr. after 
initial dose
10 meg. I.V. 
10 meg. I.V.
10 meg. I.V. 
10 meg. I.V.
0.390
0.100
0.270
0.070
0. 330 
0.100  
0.290 
0.090
0.846
1.000
1.074
1.286
|33-female-10 kg. ANTISTINE
0.5 mg./kg. I.V.
0.5 mg./kg. I.V. , 
1 hr. after 
initial dose
10 meg. I.V. 
10 meg. I.V.
10 meg. I.V. 
10 meg. I.V.
0. 390 
0.200  
0.180 
0 . 100
0.290
0.150
0.130
0.050
0.744
0.750
0.722
0.500
Ln
CO
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Fig. 10
Dog 19 Upper Marker: 0 blood pressure
Male 11 kg. Lower Marker: Time: 10 seconds
5. Norepinephrine 20 meg. I.V.
6 . Ephedrine SO^  0 .05  mg.Ag. I.V.
7. Norepinephrine 20 meg. I.V.
8 . Norepinephrine 1 m g .A g ./5  hrs. I.V. in fu sion  s ta r te d .
9. Kymograph: 1 min. on, 15 min. o f f .
10. Ephedrine SO^  0 .05  mg.Ag. I .  V. 2 hrs. a fter  in fu s io n  s tar ted .
12. Ephedrine SO4  0 .05 m g.Ag. I . V. 3 hrs. a f ter  in fu s io n  s ta r te d .
13. Kymograph: 1 min. on, 15 min. o f f .
14. Ephedrine SO4  0 .05 mg.Ag. I .  V. 4 hrs. a f te r  in fu s io n  s tar ted .
15. Kymograph: 1 min. on, 15 min. o f f .
16. Norepinephrine 1 m g .A g ./5  hrs. I .  V. in fu s ion  stopped.
17. Ephedrine SO^  0.05 mg.Ag. I .  V.
18. Kymograph; 1 min. on, 15 min. o f f .
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s ig n i f ic a n t ly  from that in  the control animals. Dog 20, died 32 minutes 
after  completion of the in fu sion  and Dog 21, had a very low blood pressure 
1 hr. and 41 min. a f te r  the end of in fusion  when k i l l e d .
Benadryl was given to Dog 22 at a dose l e v e l  of 1 mg. A g .  I .  V. 
I t  proved to  be a good augmentor at t h is  dose l e v e l  during the f i r s t  
hour of in fu sion . However, the augmenting e f f e c t  decreased during the 
ensuing hours of in fu s ion  and f a i l e d  to  protect the animal aga inst  post -1  
in fu sion  hvnotensinn. The animal was in profound shock when k i l l e d .
The same type of experiment was performed on Dog 23 using  
Pyribenzamine (1 mg.Ag. I . V.) as the augmenting agent. E s s e n t ia l ly  
the same picture developed as was found with Benadryl. The animal died 
27 minutes fo llow ing the end of infusion .
A number of experiments were performed to  determine i f  other 
antih istam in ic  compounds were capable of augmenting the pressor e f f e c t  
|of norepinephrine and epinephrine. The r e su lt s  are tabulated in  Table 
IV. In those experiments in  which a second 0.5 m g.Ag. dose of the 
augmenting agent was g iven , the "Before" readings of the areas under 
the blood pressure curves were ca lcu lated  from curves produced 45 minutes 
fo llowing the f i r s t  dose of the augmenting drug. The "After" readings 
were taken f i v e  minutes fo llowing each dose of the antih istam in ic  com­
pound.
Table IV revea ls  that ephedrine, Pyribenzamine, and Triraeton 
are very good augmenting agents. Benadryl appears to  be a r e la t iv e ly  
weaker augmenting agent. Thephorin and A n tist in e  seem to  have l i t t l e ,  
i f  any, augmenting e f f e c t .  In most ca ses ,  they in h ib it  to some degree 
the pressor-action  of norepinephrine and e p i n e p h r i n e . —
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A point worth noting i s  that those antih istam ines which augment, 
u su a l ly  augment the pressor e f f e c t  of norepinephrine to a greater degree 
than that of epinephrine (F ig . 11). This would tend to  conform with the 
report of Blaschko and Burn (29) which s ta t e s  that amine oxidase has a 
greater e f f e c t  on norepinephrine than on epinephrine. Very small doses  
of norepinephrine (0 .1  meg.) do not appear to be augmented by Pyribenzamjine 
j(Fig. 11). This f a c t  would seem to  be a paradox. I f  amine oxidase i s  
Ithe mechanism by which augmentation takes p lace , small doses of norepi­
nephrine should be augmented to  the same degree as larger doses. This 
paradox might be explained on the b a s i s  that not a l l  of the amine o x i-
i
idase has been in h ib ited .  Thus, very small doses of norepinephrine would 
jbe destroyed rapid ly  and no augmentation take p lace.
These experiments show that the antih istam in ic  properties  of 
these compounds are unrelated to  th e ir  augmenting e f f e c t  on norepi-  
Inephrine. I t  has been s ta te d  previously  that norepinephrine increases  
jhlnod histam ine, which would tend to  reduce the response to  the pressor
I
I amine. Pyribenzamine and Thephorin are both potent antihistamine com- 
! pounds and should t h e o r e t ic a l ly  have approximately equal a b i l i t y  to  
block the e f f e c t  of the histamine re leased  by norepinephrine. However, 
Pyribenzamine produces augmentation of the norepinephrine pressor e f fe c t  
w hile  Thephorin does not.
Augmentation of the pressor e f f e c t  of norepinephrine by Pyri- 
benzamine ( 0 .5 - 1  m g .A g .)  suggested that animals so  treated might be 
u se fu l  as t e s t  subjects  for  b io lo g ic a l  assay.
P a t ien ts  who harbor pheochromocytoma, for  example, excrete  free 
epinephr-ine-and—norepinephrine—i-n-amounts-ranging—from-^OO-tc-above-----
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Fig. 11
Dog 35 Upper Marker: 0 blood pressure
Male 6 .4  kg. Lower Marker: Time; 10 seconds
1. Norepinephrine 10 meg. I .  V.
2. Epinephrine 10 meg. I . V.
3. Norepinephrine 0 .1  meg. I .  V.
4. Pyribenzamine 1 m g.Ag. I .  V.
5. Norepinephrine 10 meg. I .  V.
6 . Epinephrine 10 meg. I .  V.
7. Norepinephrine 0 .1  meg. I .  V.
8 . Norepinephrine 0.05 meg. I .  V.
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3000 mcg./24 hours in  the urine. A su ccess fu l  method for the d etect ion  
of pheochromocytoma, based on the change in  blood pressure produced by 
in je c t io n  of untreated urine in to  t e s t  animals, has been described (95 ),  
The present experiments show that s e n s i t iz a t io n  of the t e s t  animal with ! 
Pyribenzamine improves the c a p a b i l i t ie s  of th is  assay procedure, s ince  
such treatment makes i t  p o ss ib le  to  " t itra te"  the concentration of
I  I
! pressor amines in  the urine in  amounts as low as 0 .01 meg./cc. A number
I of urine specimens taken from p atien ts  suspected of having pheochromo- I
! I
cytoma have been assayed by t h is  method and found to  contain from 1 0  to!
!
50 meg. of pressor substances per 1000 cc. of urine. This i s  w e l l  w ith in  
the normal range of p at ien ts  who have e s s e n t ia l  hypertension or other 
hypertensive d isorders but not pheochromocytoma.
CHAPTER V 
SUMMRY AND CONCLUSIONS
1. Long-term in fu sion  of norepinephrine in  dogs invariably shows two 
d i s t i n c t  e f f e c t s :  1 ) the blood pressure r i s e s  p rec ip itou s ly  at
f i r s t ,  but in a few minutes gradually d e c l in e s  u n t i l  i t  eventually  
a tta in s  or f a l l s  below p re-in fu sion  le v e ls ;  2 ) a fter  discontinuing  
the in fu sion , the blood pressure f a l l s  to  an even lower l e v e l ,
2. Most of the animals which were infused with norepinephrine at the 
dosage le v e ls  used in t h is  study showed by gross inspection  ischemic 
v isc e r a ,  acute passive congestion of the l i v e r ,  edema of lungs and 
lim bs, d i s te n t io n  of the stomach by gas, and recent foca l  hemorrnagejs 
of the lungs.
3. The r e s u l t s  of long-term in fu s io n  of norepinephrine ind ica te  a pro­
g r e s s iv e ly  decreasing cardiovascular response to the pressor e f f e c t  
of th is  agent.
4. Dibenzyline in  doses of 5-10 m g.Ag. I .  V. did not protect against  
the depressor e f f e c t  of the infused norepinephrine. To the contrary 
i t  caused a reversal of the pressor e f f e c t  of norepinephrine and 
epinephrine.
5. GD-131 caused some reduction of the pressor e f f e c t  of norepinephrine 
but did not cause norepinephrine reversa l as did Dibenzyline at the
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same dose l e v e l .  ^ G D -B r '^ d  n o F p w t ë c F ^ i n à r  t h r p o ^ t - i S ï i ï i ^  
hypotension due to  norepinephrine. No conclusions can be drawn 
from these s tu d ie s  concerning vasodepressor m aterial (VDM) as a 
contributing fac tor  in  producing the vasodepressor a f t e r e f f e c t  of 
norepinephrine.
6 . The ganglion ic  blocking e f f e c t  of norepinephrine i s  not thought to
I be a major factor  in  the development of the vasodepressor e f f e c t s
of norepinephrine.
7, Blood glucose determinations in animals infused with norepinephrine 
revealed a moderate degree of hyperglycemia. This confirms previous  
reports in the l i t e r a tu r e .
S, Ephedrine, Pyribenzamine, Trimeton and Benadryl in  doses of 0 .5  mg./ 
kg. I . V. augment the pressor e f f e c t  of s in g le  doses of norepi­
nephrine and epinephrine. Ephedrine, Pyribenzamine and Benadryl 
produce an augmenting e f f e c t  in  the f i r s t  hour of an infusion of 
norepinephrine ( 1  m g .A g . /5  h r s . ) .  This e f f e c t  diminishes with  
time. None of the agents m ater ia l ly  change the end r e su lt  of nor­
epinephrine in fu sion  from that of the control experiments. However, 
the r e su lt s  of these  experiments are compatible with the theory that  
norepinephrine i s  being destroyed by amine oxidase during and 
following in fu sio n ,
9. Animals treated  with Pyribenzamine (0 .5  -1  m g.Ag. I . V.) are very 
s e n s i t iv e  to pressor substances found in  the urine of normotensive 
and hypertensive p a t ie n ts .  I t  i s  suggested that the s e n s i t iz a t io n  
of dogs by Pyribenzamine w i l l  improve the bioassay method for the
suspected of having pheochromocytoma.
ADDENDUM
Following the completion of the preliminary draft of t h is  
d is s e r ta t io n ,  a paper e n t i t le d  "Secondary f a l l  in  blood pressure  
jfollowing noradrenaline in fu sion  in  the cat" , by H. Duner and U. S. von 
Euler, appeared in  Acta Physio l.  Scandinav., 38: 355 (1957).
These authors have concluded that the f a l l  in blood pressure  
a f te r  noradrenaline i s  p ar t ly  due to a blocking e f f e c t  on transm ission  
within the vasomotor system. This in terp re ta t ion  i s  based on the  
following observations: 1 ) a fter  buffer nerve s e c t io n ,  when no counter­
regulation  i s  e f f e c t i v e  on the blood pressure, the p o s t - in fu s io n a l  t a l l
i s  enhanced and prolonged, 2 ) a f te r  adm inistration of a ganglion ic
ii
blocking agent no further block would be e f f e c t iv e  and the f a l l  i s  re -
t
duced to a s h o r t - la s t in g  fract ion .
The second statement appears to  be an erroneous assumption, 
for  th e o r e t ic a l ly ,  ganglion ic  blockade should g iv e  the same end r esu lt  
as sect ion in g  of the buffer nerves. I t  i s  f e l t  that the conclusions  
presented in  t h is  paper are not warranted by the data presented. To 
the contrary i t  would seem more probable that th e ir  data support more
I
f u l ly  the conclusions of t h is  d is se r ta t io n  on t h i s  matter.
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